In a report released on August 7, Puneet Souda from Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), with a price target of $35.00. Puneet Souda has given his Buy ...
SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its strategic ...
B, as a powerful regulator that enhances wheat’s regeneration efficiency by balancing cytokinin levels and activating regeneration-related genes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback